{
    "clinical_study": {
        "@rank": "153048", 
        "arm_group": [
            {
                "arm_group_label": "Curcumin Group", 
                "arm_group_type": "Experimental", 
                "description": "Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.\nPatients take 3 grams of curcumin (as 6 capsules 500 mg)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.\nPatients take 3 grams of placebo (as 6 capsules 500 mg)"
            }
        ], 
        "brief_summary": {
            "textblock": "Prostate cancer is the second most incident cancer among male population worldwide.\n      Radiation therapy by itself or along with surgery and chemotherapy are the main treatments\n      for prostate cancer however prostate cancer cells are only modestly responsive or even\n      unresponsive to the cytotoxic effects of radiotherapy. Recently some in vitro and in vivo\n      studies showed radiosensitizing and radioprotective effects for curcumin. No clinical trial\n      has been done in this area and it is not yet known whether radiation therapy is more\n      effective with or without curcumin supplements in treating patients with prostate cancer."
        }, 
        "brief_title": "Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer", 
        "condition": [
            "Prostate Cancer", 
            "Radiation Therapy"
        ], 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed adenocarcinoma of the prostate\n\n          2. Age range of 50-80\n\n          3. ECOG performance status 0-1\n\n          4. Life expectancy > 5 years\n\n          5. Must be enrolled in a social security program\n\n          6. No other cancer, except basal cell skin cancer, that has been treated or relapsed\n             within the past 5 years\n\n          7. No severe uncontrolled hypertension (systolic BP \u2265 160 mm Hg or diastolic BP \u2265 90 mm\n             Hg)\n\n          8. No contraindication to luteinizing hormone-releasing hormone agonists\n\n          9. No contraindication to pelvic irradiation (e.g., scleroderma, chronic inflammatory\n             gastrointestinal disease)\n\n         10. No hip prosthesis\n\n         11. Must not be deprived of liberty or under guardianship\n\n         12. No geographical, social, or psychological reasons that would preclude follow up\n\n        Exclusion Criteria:\n\n          1. Clinical stage T3 or T4\n\n          2. Gleason score \u2265 8\n\n          3. Serum PSA \u2265 20 ng/mL and \u2264 100 ng/mL\n\n          4. other prior surgery for prostate cancer\n\n          5. concurrent participation in another clinical trial which would require approval upon\n             entry to this trial\n\n          6. Gastrointestinal disorders such as IBD, reflux and peptic ulcers\n\n          7. Any adverse reaction to curcumin"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917890", 
            "org_study_id": "Radiation Therapy And Curcumin"
        }, 
        "intervention": [
            {
                "arm_group_label": "Curcumin Group", 
                "description": "Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.\nPatients take 3 grams of BCM95 Curcumin (as 6 \u00d7 500 mg capsules)", 
                "intervention_name": "Curcumin", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "turmeric pigment"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.\nPatients take 3 grams of roasted rice powder (as 6 \u00d7 500 mg capsules)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Curcumin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "curcumin", 
            "radioprotective", 
            "radiosensitizer"
        ], 
        "lastchanged_date": "August 5, 2013", 
        "location": {
            "contact": {
                "last_name": "Hadi Molana, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "556432412"
                }, 
                "name": "Oncology and radiotherapy department, Besat Hospital"
            }, 
            "investigator": {
                "last_name": "Jalal Hejazi, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Radiation Therapy With or Without Curcumin Supplement in Treating Patients With Prostate Cancer", 
        "overall_contact": {
            "email": "r.rastmanesh@gmail.com", 
            "last_name": "Reza Rastmanesh, PhD", 
            "phone": "+9821-22357484", 
            "phone_ext": "253"
        }, 
        "overall_official": {
            "affiliation": "Clinical Nutrition & Dietetics Dept., Shahid Beheshti University of Medical Sciences,", 
            "last_name": "Reza Rastmanesh, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Iran: National Nutrition and Food Technology Research Inistitute", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess this outcome the results of magnetic resonance spectroscopy (MRS)will be compared between the 2 groups 1 week before radiation therapy and 3 months after radiotherapy completion. Also prostate specific antigen (PSA)rebound will be compared between the 2 groups after 1 year. Side effects of treatment during 1 year after treatment completion will be compared between the 2 groups using questionnaires and physical examination", 
            "measure": "Biochemical or clinical progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917890"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shaheed Beheshti Medical University", 
            "investigator_full_name": "Reza Rastmanesh", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Quality of life related issues will be compared between the 2 groups 1 week before radiotherapy onset and 3 months and 1 year after radiotherapy completion using EORTC QLQ-C30 and EORTC QLQ - PR25", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Sexual dysfunction score will be compared between the 2 groups 1 week before radiotherapy onset and 3 months and 1 year after radiotherapy completion using EORTC QLQ - PR25", 
                "measure": "Sexual dysfunction score", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "It will be measured in plasma 1 week before radiotherapy onset and 3 month after radiotherapy completion using biochemical kits. (mg/L)", 
                "measure": "C-reactive protein (hs-CRP)", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "They will be measured in plasma 1 week before radiotherapy onset and 3 month after radiotherapy completion using biochemical kits. (pg/ml)", 
                "measure": "Inflammatory factors (tumor necrosis factor alpha (TNF-alpha), Interleukin 1 beta (IL1-beta)and Interleukin 6  (ILl-6))", 
                "safety_issue": "No", 
                "time_frame": "5 monthes"
            }, 
            {
                "description": "They will be measured in plasma 1 week before radiotherapy onset and 3 month after radiotherapy completion using biochemical kits. (U/L)", 
                "measure": "Antioxidant enzymes (Catalase, super oxide dismutase (SOD), glutathione-S- transferase (GST), glutathione peroxidase (GPX))", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "measuring activity and gene expression of the enzyme in peripheral blood mono-nuclear cell (PBMC)1 week before radiotherapy onset and 3 months after radiotherapy.", 
                "measure": "cycloxygenase 2 (COX2)", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "measuring activity and gene expression in peripheral blood mono-nuclear cell (PBMC)1 week before radiotherapy onset and 3 months after radiotherapy.", 
                "measure": "Nuclear factor KB (NF-\u039aB)", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }
        ], 
        "source": "Shahid Beheshti Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shahid Beheshti Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}